Astrazeneca ADR Stock
Your prediction
Astrazeneca ADR Stock
The price for the Astrazeneca ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.650%).
So far the community has only identified positive things for Astrazeneca ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | -0.650% | -0.645% | 1.316% | 20.313% | 20.313% | 17.021% | 71.875% |
| GSK plc ADR | -2.390% | -1.923% | -1.923% | 24.390% | 24.390% | 19.298% | 4.615% |
| Bayer AG ADR | 1.700% | 4.678% | 30.657% | 90.426% | 80.444% | -31.154% | -23.504% |
| Novo Nordisk A/S ADR | -0.230% | 4.015% | -1.384% | -58.894% | -48.864% | -65.385% | -25.652% |
News
Why AstraZeneca Stock Bumped Higher Today
AstraZeneca (NASDAQ: AZN) stock finished the trading week in style, rising by nearly 3% in value on Friday. That was due to news from the company that it's expanding its manufacturing footprint in
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
MIAMI, FL / ACCESS Newswire / November 20, 2025 / OMP, a global leader in supply chain planning solutions, brought together global supply chain executives, technology innovators, and
Where Will IonQ Be in 10 Years?
Ten years go by quickly. Duke University professors Chris Monroe and Jungang Kim founded IonQ (NYSE: IONQ) in 2015. Their goal was to develop a commercially viable quantum computer. They succeeded.